Publications

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

The Statement of Expectations sets out the role for the Aged Care Quality and Safety Commission in preparing the sector for the new Aged Care Act.

This document outlines the updates to the LSDP’s testing requirements for Pompe disease, Gaucher disease (type 1), and mucopolysaccharidosis types I, II, and VI arising from the LSDP Expert Panel’s Medicines Reviews Recommendations.

This fact sheet supports care recipients to understand their monthly statement and the responsible use of Home Care Package funds. It accompanies the Care Recipient Guidance – Understanding your Home Care Package statement.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for hereditary tyrosinaemia (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for late-infantile onset Batten disease under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for infantile-onset or late-onset Pompe disease under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type I (MPS I) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type II (MPS II) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type IVA (MPS IVA) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type VI (MPS VI) under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.